IMUNOFAN Nasal Spray

IMUNOFAN Nasal Spray  intended for intranasally administration. The advantages of this form of release are ease of use and speed of action. 

Imunofan is synthesized on the basis of the natural peptide hormone of the thymus gland - thymopoietin. The drug contains as an active pharmacological substance a peptide, which is a chain of six amino acid residues.

Imunofan is not an immune stimulant, just like an immunosuppressant. Imunofan has a modulating effect - it returns immunity indicators to the boundaries of reference values. It increases low and reduces the activity of elevated indicators, ensuring the safety of the drug, as well as the effectiveness and balance of the body's immune response.

Main components: arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine diacetate (as anhydrous and free of acetic acid) 45 mcg/dose

Excipients: glycine (5 mg) sodium chloride (0.7 mg), benzalkonium chloride (0.014 mg), disodium edetate (0.007 mg), purified water (up to 0.14 ml)

Action:

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. The pharmacological action is based on achieving three main effects: correcting the immune system, restoring the balance of the body's oxidative-antioxidant reaction and inhibiting multidrug resistance mediated by proteins of the cell's transmembrane transport pump.

The action of the drug begins to develop within 2-3 hours (fast phase) and lasts up to 4 months (medium and slow phases).
During the fast phase (duration - up to 2 - 3 days), first of all, the detoxification effect is manifested - the antioxidant defense of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol levels and the production of inflammatory mediators. With toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.
During the middle phase (begins after 2-3 days, duration - up to 7-10 days) there is an increase in the reactions of phagocytosis and the death of intracellular bacteria and viruses.
During the slow phase (begins to develop on the 7th - 10th day, duration up to 4 months), the immunoregulatory effect of the drug is manifested - the restoration of disturbed indicators of cellular and humoral immunity. During this period, there is a restoration of the immunoregulatory index, there is an increase in the production of specific antibodies. The effect of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reaginic IgE antibodies and does not enhance the immediate hypersensitivity reaction. Imunofan stimulates the formation of IgA in its congenital deficiency.
Imunofan effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the action of chemotherapeutic drugs.

Indications:

It is used in adults and children over 2 years of age for the prevention and treatment of immunodeficiency and toxic conditions, acute and chronic infectious and inflammatory diseases.

Contraindications:

Hypersensitivity, pregnancy complicated by Rhesus conflict, children under 2 years of age.

Pregnancy and lactation: 

During pregnancy and during breastfeeding, it is used only if the intended benefit to the mother outweighs the potential risk to the fetus and child.

Dosage form:

Transparent or almost transparent, colorless or slightly yellowish liquid. A slight characteristic odor is allowed.

Dosage and administration:

Intranasally. When using the bottle should be held vertically, spray up. Remove the protective cap from the atomizer. Before the first use, fill the dosing pump by pressing the wide rim of the sprayer 3-4 times. Insert the nebulizer into the nasal passage with the head upright. Press the wide rim of the atomizer once until it stops. One dose of the drug contains 45 mcg of imunofan. The daily dose should not exceed 180 mcg.
In the complex therapy of acute and chronic infectious and inflammatory diseases accompanied by symptoms
intoxication and immunodeficiency, imunofan is prescribed 1 dose (45 mcg) in each nasal passage 2 times a day, daily for 10-15 days.
With opportunistic infections (cytomegalovirus and herpetic infection, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis):
- 1 dose (45 mcg) in each nasal passage 2 times a day, daily, the course of treatment is 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.
In chronic viral hepatitis and chronic brucellosis:
- 1 dose (45 mcg) in each nasal passage 1 time per day, daily, course of treatment 10-15 days, to prevent relapse, repeat courses should be carried out after 4-6 months.
In the treatment regimen for patients with HIV infection:
- 1 dose (45 mcg) in each nasal passage 1 time per day, daily, for 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.
In the treatment of cancer patients in the scheme of radical combined treatment (chemo-radiation therapy and surgery):
- 1 dose (45 mcg) in each nasal passage 1 time per day, daily, for 8-10 days before chemo-radiation therapy and surgery, followed by continuation of the course throughout the entire period of treatment.
In patients with a widespread tumor process (III-IV stages) of various localization in terms of complex or symptomatic therapy:
- 1 dose (45 mcg) in each nasal passage 1 time per day, daily, for 8-10 days. If necessary, and the presence of pronounced symptoms of toxicosis, it is recommended to repeat the course.

Side effects: allergic reactions to the components of the drug.

Drug interaction: the action of Imunofan does not depend on the production of PGE2 and the administration of the drug is possible in combination with anti-inflammatory (steroidal and non-steroidal) drugs.

Special instructions: as a result of the activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

Influence on the ability to drive vehicles and mechanisms: The drug does not affect the ability to drive vehicles, mechanisms.

Storage temperature 2℃ to 8℃

Guaranteed authenticity and quality:

100% Original from LLP BIONOKS (Russia)

Patents and sertificates:

The drug contains as an active pharmacological substance a peptide representing a chain of six amino acid residues, the composition and sequence of which are protected by RF patent No. 2062096.

LLP BIONOKS (Russia)